Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D. Welslau M, et al. Cancer. 2014 Mar 1;120(5):642-51. doi: 10.1002/cncr.28465. Epub 2013 Nov 12. Cancer. 2014. PMID: 24222194 Free article. Clinical Trial.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Verma S, et al. Among authors: welslau m. N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. N Engl J Med. 2012. PMID: 23020162 Free PMC article. Clinical Trial.
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.
Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, Welslau M, Wang G, Dawkins F, de Boer CJ, Schrijvers D. Heidenreich A, et al. Among authors: welslau m. Ann Oncol. 2013 Feb;24(2):329-336. doi: 10.1093/annonc/mds505. Epub 2012 Oct 26. Ann Oncol. 2013. PMID: 23104724 Free article. Clinical Trial.
Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in Germany.
Jackisch C, Welslau M, Schoenegg W, Selbach J, Harich HD, Schröder J, Schmidt M, Göhler T, Eustermann H, Ringel R, Hinke A. Jackisch C, et al. Among authors: welslau m. Breast. 2014 Oct;23(5):603-8. doi: 10.1016/j.breast.2014.06.003. Epub 2014 Jul 8. Breast. 2014. PMID: 25012046 Free article.
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Diéras V. Krop IE, et al. Among authors: welslau m. Ann Oncol. 2015 Jan;26(1):113-119. doi: 10.1093/annonc/mdu486. Epub 2014 Oct 29. Ann Oncol. 2015. PMID: 25355722 Free PMC article. Clinical Trial.
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich HD, Tesch H, Wohlfarth T, Eustermann H, Hinke A. Jackisch C, et al. Among authors: welslau m. BMC Cancer. 2014 Dec 8;14:924. doi: 10.1186/1471-2407-14-924. BMC Cancer. 2014. PMID: 25487774 Free PMC article.
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.
Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A. Hecht JR, et al. Among authors: welslau m. Cancer Manag Res. 2015 Jun 15;7:165-73. doi: 10.2147/CMAR.S61408. eCollection 2015. Cancer Manag Res. 2015. PMID: 26109878 Free PMC article.
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas. Rummel M, et al. Among authors: welslau m. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655425 Clinical Trial.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Diéras V, et al. Among authors: welslau m. Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526536 Free PMC article. Clinical Trial.
Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial.
Riese C, Weiß B, Borges U Jr, Beylich A, Dengler R, Hermes-Moll K, Welslau M, Baumann W. Riese C, et al. Among authors: welslau m. Support Care Cancer. 2017 Nov;25(11):3475-3483. doi: 10.1007/s00520-017-3770-0. Epub 2017 Jun 9. Support Care Cancer. 2017. PMID: 28597253 Clinical Trial.
77 results